KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Debt to Equity (2017 - 2026)

Aquestive Therapeutics has reported Debt to Equity over the past 9 years, most recently at -$1.11 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 106.11% year-over-year to -$1.11; the TTM value through Dec 2025 reached -$1.11, down 106.11%, while the annual FY2025 figure was -$1.11, 106.11% down from the prior year.
  • Debt to Equity for Q4 2025 was -$1.11 at Aquestive Therapeutics, up from -$8.83 in the prior quarter.
  • Over five years, Debt to Equity peaked at -$0.26 in Q4 2023 and troughed at -$8.83 in Q3 2025.
  • A 5-year average of -$0.99 and a median of -$0.56 in 2022 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: soared 74.88% in 2021 and later plummeted 1181.69% in 2025.
  • Year by year, Debt to Equity stood at -$0.65 in 2021, then surged by 32.57% to -$0.44 in 2022, then skyrocketed by 41.23% to -$0.26 in 2023, then crashed by 109.14% to -$0.54 in 2024, then crashed by 106.11% to -$1.11 in 2025.
  • Business Quant data shows Debt to Equity for AQST at -$1.11 in Q4 2025, -$8.83 in Q3 2025, and -$0.48 in Q2 2025.